Previously Diagnosed HIV Infection in Patients with COVID-19 and Advanced HIV Disease Improves Their Survival

IF 0.5 Q4 INFECTIOUS DISEASES
A. E. Tsygankova, A. Gerasimov, V. Chulanov, O. Darvina, K. Umbetova, V. A. Malov, E. Volchkova
{"title":"Previously Diagnosed HIV Infection in Patients with COVID-19 and Advanced HIV Disease Improves Their Survival","authors":"A. E. Tsygankova, A. Gerasimov, V. Chulanov, O. Darvina, K. Umbetova, V. A. Malov, E. Volchkova","doi":"10.5812/archcid-142231","DOIUrl":null,"url":null,"abstract":"Background: Currently, the global HIV epidemic remains ongoing, with a significant number of patients having undiagnosed advanced HIV disease. Providing medical care to patients with both COVID-19 and advanced HIV disease presents specific challenges due to the simultaneous lung damage caused by the SARS-CoV-2 virus and opportunistic pathogens. Objectives: This study aimed to explain the rationale behind recommending HIV screening for patients with severe COVID-19. Methods: A single-center retrospective cohort study was conducted using electronic medical records from a specialized hospital in Moscow that focused on coinfection with HIV/COVID-19. Among the 3,563 patients hospitalized in the relevant departments during the study period, 408 patients were included based on the inclusion/exclusion criteria. Out of the 408 patients with both COVID-19 and advanced HIV disease, 132 individuals were newly diagnosed with HIV infection, while 276 individuals had a previously established HIV diagnosis. Results: The mortality rate in the group of patients with COVID-19 and advanced HIV disease was 31.7% (95% CI, 27.3 - 36.3%). Among patients with COVID-19 and newly diagnosed advanced HIV disease, the mortality rate was 45.5% (95% CI, 37.1 - 54%), while in the group of patients with previously diagnosed advanced HIV disease, the mortality rate was 25% (95% CI, 20.2 - 30.4%). The proportion of individuals with critical CT-4 lung disease in the first group was 32.3% compared to 9.4% in the second group (P < 0.001). The median CD4+ count was 20 cells/µL in the first group compared with 88 cells/µL in the second group (P < 0.001). Conclusions: The presence of pneumocystis pneumonia increased the risk of death by 2.51 times in patients with COVID-19 and newly diagnosed advanced HIV disease. Additionally, Kaposi's sarcoma increased the risk of death by 1.31 times in the same patient group. Furthermore, the detection of HIV infection for the first time during hospitalization due to COVID-19 in the entire study cohort increased the risk of death by 2.21 times.","PeriodicalId":51793,"journal":{"name":"Archives of Clinical Infectious Diseases","volume":"81 9","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Clinical Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/archcid-142231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Currently, the global HIV epidemic remains ongoing, with a significant number of patients having undiagnosed advanced HIV disease. Providing medical care to patients with both COVID-19 and advanced HIV disease presents specific challenges due to the simultaneous lung damage caused by the SARS-CoV-2 virus and opportunistic pathogens. Objectives: This study aimed to explain the rationale behind recommending HIV screening for patients with severe COVID-19. Methods: A single-center retrospective cohort study was conducted using electronic medical records from a specialized hospital in Moscow that focused on coinfection with HIV/COVID-19. Among the 3,563 patients hospitalized in the relevant departments during the study period, 408 patients were included based on the inclusion/exclusion criteria. Out of the 408 patients with both COVID-19 and advanced HIV disease, 132 individuals were newly diagnosed with HIV infection, while 276 individuals had a previously established HIV diagnosis. Results: The mortality rate in the group of patients with COVID-19 and advanced HIV disease was 31.7% (95% CI, 27.3 - 36.3%). Among patients with COVID-19 and newly diagnosed advanced HIV disease, the mortality rate was 45.5% (95% CI, 37.1 - 54%), while in the group of patients with previously diagnosed advanced HIV disease, the mortality rate was 25% (95% CI, 20.2 - 30.4%). The proportion of individuals with critical CT-4 lung disease in the first group was 32.3% compared to 9.4% in the second group (P < 0.001). The median CD4+ count was 20 cells/µL in the first group compared with 88 cells/µL in the second group (P < 0.001). Conclusions: The presence of pneumocystis pneumonia increased the risk of death by 2.51 times in patients with COVID-19 and newly diagnosed advanced HIV disease. Additionally, Kaposi's sarcoma increased the risk of death by 1.31 times in the same patient group. Furthermore, the detection of HIV infection for the first time during hospitalization due to COVID-19 in the entire study cohort increased the risk of death by 2.21 times.
COVID-19 和晚期艾滋病患者中既往确诊的艾滋病毒感染可改善他们的存活率
背景:目前,全球艾滋病毒疫情仍在持续,大量患者患有未确诊的晚期艾滋病毒疾病。由于 SARS-CoV-2 病毒和机会性病原体同时对肺部造成损害,因此为 COVID-19 和晚期艾滋病患者提供医疗护理面临特殊挑战。研究目的本研究旨在解释建议对严重 COVID-19 患者进行 HIV 筛查的理由。研究方法利用莫斯科一家专科医院的电子病历开展了一项单中心回顾性队列研究,重点关注合并感染 HIV/COVID-19 的患者。在研究期间,相关科室共收治了 3,563 名住院患者,其中 408 名患者符合纳入/排除标准。在 408 名同时患有 COVID-19 和晚期 HIV 疾病的患者中,132 人是新诊断出的 HIV 感染者,276 人之前已确诊为 HIV 感染者。研究结果COVID-19 和晚期艾滋病患者的死亡率为 31.7%(95% CI,27.3 - 36.3%)。在 COVID-19 和新确诊的晚期艾滋病患者中,死亡率为 45.5%(95% CI,37.1 - 54%),而在既往确诊的晚期艾滋病患者中,死亡率为 25%(95% CI,20.2 - 30.4%)。第一组中患有 CT-4 重症肺病的比例为 32.3%,而第二组为 9.4%(P < 0.001)。第一组 CD4+ 细胞计数中位数为 20 cells/µL,第二组为 88 cells/µL(P < 0.001)。结论在 COVID-19 和新确诊的晚期艾滋病患者中,出现肺孢子菌肺炎会使死亡风险增加 2.51 倍。此外,卡波西肉瘤也会使同一患者组的死亡风险增加 1.31 倍。此外,在整个研究队列中,因 COVID-19 而住院期间首次发现感染艾滋病毒的患者的死亡风险增加了 2.21 倍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
46
期刊介绍: Archives of Clinical Infectious Diseases is a peer-reviewed multi-disciplinary medical publication, scheduled to appear quarterly serving as a means for scientific information exchange in the international medical forum. The journal particularly welcomes contributions relevant to the Middle-East region and publishes biomedical experiences and clinical investigations on prevalent infectious diseases in the region as well as analysis of factors that may modulate the incidence, course, and management of infectious diseases and pertinent medical problems in the Middle East.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信